GPER mediates activation of HIF1α/VEGF signaling by estrogens

Cancer Research

Volumn 74, Issue 15, 2014, Pages 4053-4064

  De Francesco, Ernestina Marianna ^a   Pellegrino, Michele ^a   Santolla, Maria Francesca ^a   Lappano, Rosamaria ^a   Ricchio, Emilia ^a   Abonante, Sergio ^b   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Regional Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 ( 6 BROMOBENZOL[1,3]DIODO 5 YL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLIN8YL]ETHANONE; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; G PROTEIN COUPLED RECEPTOR 30; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; UNCLASSIFIED DRUG; VASCULOTROPIN; 1-(4-(6-BROMOBENZO(1,3)DIOXOL-5-YL)-3A,4,5,9B-TETRAHYDRO-3H-CYCLOPENTA(C)QUINOLIN-8-YL)ETHANONE; CYCLOPENTANE DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; QUINOLINE DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL GROWTH; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOPENTANES; ESTRADIOL; ESTROGENS; FEMALE; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; QUINOLINES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905482195     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3590     Document Type: Article

References (50)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012;62:220-41.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
3. Zhou Z, Qiao JX, Shetty A, Wu G, Huang Y, Davidson NE, et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci 2013. [Epub ahead of print].
4. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010;204:105-14.
5. Mizukami Y. In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J 2010;57:101-7.
6. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, et al. G protein coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17b-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007;7:1859-66.
7. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009;28:523-32.
8. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;2:207-12.
9. Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr Cancer Drug Targets 2012;12:531-42.
10. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009;5:421-7.
11. Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, et al. MIBE acts as antagonist ligand of both estrogen receptor a and GPER in breast cancer cells. Breast Cancer Res 2012;14:R12.
12. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptornegative breast cancer cells. Mol Cell Endocrinol 2010;320:162-70.
13. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000;14:1649-60.
14. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-32.
15. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625-30.
16. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006;12:6359-66.
17. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007;196:386.e1-9; discussion 386.e9-11.
18. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009;114:465-71.
19. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 2011;128:457-66.
20. Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res 2013;15:R114.
21. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17b-estradiol-induced gene expression and migration in breast cancer associated fibroblasts. Cancer Res 2010;70:6036-46.
22. Gomes FG, Nedel F, Alves AM, Nör JE, Tarquinio SB. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 2013;92:101-7.
23. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213.
24. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69 Suppl 3:11-6.
25. Sengupta K, Banerjee S, Saxena N, Banerjee SK. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-a dependent pathway. Int J Oncol 2003;22:609-14.
26. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, et al. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor α and SP proteins. Oncogene 2004;23:1052-63.
27. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-1.
28. Sudhagar S, Sathya S, Lakshmi BS. Rapid non-genomic signalling by 17b-oestradiol through c-Src involves mTOR-dependent expression of HIF-1a in breast cancer cells. Br J Cancer 2011;105:953-60.
29. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1a/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res 2013;15:R64.
30. Gerdes MJ, Myakishev M, Frost NA, Rishi V, Moitra J, Acharya A, et al. Activator protein activity regulates epithelial tumor cell identity. Cancer Res 2006;66:7578-88.
31. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer. Endocrinology 2008;149:3799-08.
32. da Silva BB, Lopes-Costa PV, dos Santos AR, de Sousa-Júnior EC, Alencar AP, Pires CG, et al. Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer. Eur J Gynaecol Oncol 2009;30:285-88.
33. Rafikova O, Rafikov R, Kumar S, Sharma S, Aggarwal S, Schneider F, et al. Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med 2013;56:28-43.
34. Staton CA, Reed MW, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 2009;90:195-21.
35. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 2001;21:6-12.
36. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
37. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
38. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-14.
39. Hyder S, Nawaz Z, Chiappetta C, Stancel G. Identification of functional estrogen response elements in the gene coding for the potent vascular endothelial growth factor. Cancer Res 2000;60:3183-90.
40. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL, Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 1996;56:3954-60.
41. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissues VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898-05.
42. Smith HO, Stephens ND, Qualls CR, Fligelman T, Wang T, Lin CY, et al. The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma. Mol Oncol 2013;7:41-54.
43. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
44. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1, regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005;37:535-40.
45. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
46. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-01.
47. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumorpromoting cell type. Cell Cycle 2006, 5:1597-601.
48. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-37.
49. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87:213-19.
50. Xie B, Tam NN, Tsao SW, Wong YC. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br J Cancer 1999;81:1335-43.